Quotient Wealth Partners LLC Has $472,000 Holdings in Amgen Inc. (NASDAQ:AMGN)

Quotient Wealth Partners LLC reduced its position in Amgen Inc. (NASDAQ:AMGN) by 5.9% during the 4th quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm owned 1,811 shares of the medical research company’s stock after selling 113 shares during the quarter. Quotient Wealth Partners LLC’s holdings in Amgen were worth $472,000 at the end of the most recent quarter.

Several other hedge funds and other institutional investors also recently made changes to their positions in AMGN. AMF Tjanstepension AB boosted its stake in Amgen by 16.9% in the third quarter. AMF Tjanstepension AB now owns 120,389 shares of the medical research company’s stock valued at $38,825,000 after buying an additional 17,387 shares in the last quarter. Mechanics Bank Trust Department lifted its holdings in shares of Amgen by 39.5% in the third quarter. Mechanics Bank Trust Department now owns 7,749 shares of the medical research company’s stock worth $2,497,000 after acquiring an additional 2,195 shares during the last quarter. Matrix Asset Advisors Inc. NY boosted its stake in shares of Amgen by 5.3% in the 3rd quarter. Matrix Asset Advisors Inc. NY now owns 47,449 shares of the medical research company’s stock valued at $15,289,000 after purchasing an additional 2,381 shares in the last quarter. Retirement Planning Group LLC grew its holdings in shares of Amgen by 304.3% during the 3rd quarter. Retirement Planning Group LLC now owns 3,513 shares of the medical research company’s stock valued at $1,132,000 after purchasing an additional 2,644 shares during the last quarter. Finally, Carnegie Investment Counsel increased its position in Amgen by 3.8% during the 3rd quarter. Carnegie Investment Counsel now owns 99,420 shares of the medical research company’s stock worth $32,034,000 after purchasing an additional 3,660 shares in the last quarter. 76.50% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

A number of analysts have weighed in on the stock. UBS Group decreased their target price on shares of Amgen from $335.00 to $326.00 and set a “neutral” rating on the stock in a research note on Thursday, October 31st. Jefferies Financial Group restated a “buy” rating and set a $380.00 price objective on shares of Amgen in a research report on Tuesday, November 12th. Cantor Fitzgerald reiterated an “overweight” rating and issued a $405.00 target price on shares of Amgen in a research report on Tuesday, October 22nd. Piper Sandler reduced their price target on Amgen from $344.00 to $310.00 and set an “overweight” rating on the stock in a report on Thursday, January 2nd. Finally, Piper Sandler Companies reiterated an “overweight” rating and issued a $310.00 price objective on shares of Amgen in a report on Thursday, January 2nd. Two investment analysts have rated the stock with a sell rating, ten have assigned a hold rating, twelve have assigned a buy rating and one has assigned a strong buy rating to the company. According to MarketBeat, the company currently has a consensus rating of “Hold” and an average target price of $313.23.

Insider Buying and Selling at Amgen

In related news, SVP Nancy A. Grygiel sold 1,589 shares of the company’s stock in a transaction dated Wednesday, February 5th. The shares were sold at an average price of $304.47, for a total value of $483,802.83. Following the sale, the senior vice president now owns 7,210 shares in the company, valued at $2,195,228.70. This represents a 18.06 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available at this link. Insiders own 0.69% of the company’s stock.

Amgen Price Performance

AMGN stock opened at $293.54 on Monday. The company has a debt-to-equity ratio of 9.62, a current ratio of 1.26 and a quick ratio of 0.96. The company’s 50-day moving average is $272.26 and its 200-day moving average is $303.00. The stock has a market capitalization of $157.79 billion, a PE ratio of 38.88, a price-to-earnings-growth ratio of 3.01 and a beta of 0.56. Amgen Inc. has a 1 year low of $253.30 and a 1 year high of $346.85.

Amgen (NASDAQ:AMGN) last announced its quarterly earnings data on Tuesday, February 4th. The medical research company reported $5.31 EPS for the quarter, beating analysts’ consensus estimates of $5.04 by $0.27. Amgen had a return on equity of 176.32% and a net margin of 12.24%. Equities research analysts expect that Amgen Inc. will post 20.59 EPS for the current fiscal year.

Amgen Increases Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Friday, March 7th. Shareholders of record on Friday, February 14th will be issued a dividend of $2.38 per share. This is an increase from Amgen’s previous quarterly dividend of $2.25. The ex-dividend date is Friday, February 14th. This represents a $9.52 annualized dividend and a yield of 3.24%. Amgen’s dividend payout ratio is presently 119.21%.

Amgen Company Profile

Amgen Inc discovers, develops, manufactures, and delivers human therapeutics worldwide. The company's principal products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Prolia to treat postmenopausal women with osteoporosis; XGEVA for skeletal-related events prevention; Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization; Nplate for the treatment of patients with immune thrombocytopenia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; Aranesp to treat a lower-than-normal number of red blood cells and anemia; EVENITY for the treatment of osteoporosis in postmenopausal for men and women; Vectibix to treat patients with wild-type RAS metastatic colorectal cancer; BLINCYTO for the treatment of patients with acute lymphoblastic leukemia; TEPEZZA to treat thyroid eye disease; and KRYSTEXXA for the treatment of chronic refractory gout.